AIM: To assess the role of breast ultrasonography as a complement to negative mammography in radiologically dense breasts. MATERIAL AND METHODS: Out of a total series of 49,044 consecutive mammograms reported as negative in asymptomatic women, 25,665 (52.3%) were coded as dense (BI-RADS D3-4) and ultrasonography was recommended. Due to organizational problems, ultrasonography was performed immediately or within 1 month only in 5,227 cases, representing the study series. RESULTS: Two cancers were detected at immediate ultrasonography (0.03%). The cancer detection rate in women aged 40-49 and 50-69 years was 0.002% and 0.07%, respectively. The benign biopsy rate was 0.5% for core biopsies and 0.02% for surgical biopsies. The cost per ultrasonography-assessed woman was Euro 56.05, whereas the cost per additional mammographically occult but ultrasonography-detected cancer was Euro 146,496.53. The mammograms of the 2 cancer cases underwent blind review by an expert reader and were confirmed as negative. DISCUSSION: Our findings show a low cancer detection rate, substantially lower compared to other clinical studies of ultrasonography in dense breasts, though in accordance with preliminary evidence from an Italian randomized clinical trial within a population-based screening program. The policy of adding ultrasonography to negative mammography in dense breasts seems to have very limited cost-effectiveness, and should not be adopted in routine practice before results of ongoing clinical trials are available.
AIM: To assess the role of breast ultrasonography as a complement to negative mammography in radiologically dense breasts. MATERIAL AND METHODS: Out of a total series of 49,044 consecutive mammograms reported as negative in asymptomatic women, 25,665 (52.3%) were coded as dense (BI-RADS D3-4) and ultrasonography was recommended. Due to organizational problems, ultrasonography was performed immediately or within 1 month only in 5,227 cases, representing the study series. RESULTS: Two cancers were detected at immediate ultrasonography (0.03%). The cancer detection rate in women aged 40-49 and 50-69 years was 0.002% and 0.07%, respectively. The benign biopsy rate was 0.5% for core biopsies and 0.02% for surgical biopsies. The cost per ultrasonography-assessed woman was Euro 56.05, whereas the cost per additional mammographically occult but ultrasonography-detected cancer was Euro 146,496.53. The mammograms of the 2 cancer cases underwent blind review by an expert reader and were confirmed as negative. DISCUSSION: Our findings show a low cancer detection rate, substantially lower compared to other clinical studies of ultrasonography in dense breasts, though in accordance with preliminary evidence from an Italian randomized clinical trial within a population-based screening program. The policy of adding ultrasonography to negative mammography in dense breasts seems to have very limited cost-effectiveness, and should not be adopted in routine practice before results of ongoing clinical trials are available.
Authors: John R Scheel; Janie M Lee; Brian L Sprague; Christoph I Lee; Constance D Lehman Journal: Am J Obstet Gynecol Date: 2014-06-21 Impact factor: 8.661
Authors: Joy Melnikow; Joshua J Fenton; Evelyn P Whitlock; Diana L Miglioretti; Meghan S Weyrich; Jamie H Thompson; Kunal Shah Journal: Ann Intern Med Date: 2016-01-12 Impact factor: 25.391
Authors: Monika Nothacker; Volker Duda; Markus Hahn; Mathias Warm; Friedrich Degenhardt; Helmut Madjar; Susanne Weinbrenner; Ute-Susann Albert Journal: BMC Cancer Date: 2009-09-20 Impact factor: 4.430